Deflazacort entered the pharmaceutical landscape at a time when long-term steroid use brought serious concerns about side effects. Researchers working during the late 1960s and early 1970s sought an option that helped patients manage inflammation and immune responses with less risk. Early trials in Italy and Spain highlighted that deflazacort, a synthetic glucocorticoid, allowed for effective treatment with fewer metabolic disruptions. Over the decades, the drug gained traction across Europe and Latin America. In the United States, a much slower regulatory process kept it mostly out of reach until the FDA gave approval for Duchenne muscular dystrophy in 2017. My own research in clinical practice circles found physicians eager for alternatives to prednisone, especially for pediatric patients who faced stunted growth and osteoporosis. Tradition and evidence pushed doctors to keep looking for safer, more tolerable corticosteroids, and deflazacort entered that conversation with strong supporting data.
Pharmacies worldwide recognize deflazacort as a powerful anti-inflammatory option, mostly used for autoimmune diseases, chronic lung problems, and muscular dystrophy. Unlike its relatives, such as prednisone or dexamethasone, it allows for a lower impact on calcium metabolism and blood sugar spikes. It comes as both tablets and oral suspension—accessible for adults and kids alike. Deflazacort’s biggest draw, based on physician experience, rests in its better side effect profile for bones and weight gain. For families facing Duchenne muscular dystrophy, it shifted the quality of daily life—kids remaining active for longer periods and parents worrying less about permanent bone damage.
Deflazacort belongs to the oxazoline derivatives. Its chemical framework includes a 21-acetyloxy-11β,17-dihydroxy-16α-methylpregna-1,4-diene-3,20-dione structure. White or almost white crystalline powder describes its appearance. It dissolves slowly in water but more readily in methanol, ethanol, and chloroform, which guides its preparation and storage. In the lab, melting points hover around 165–168°C, with high purity samples displaying consistent crystallinity. The molecular formula C25H31NO6 and a molecular weight of 441.52 g/mol shape drug design and delivery forms. Comparisons with other glucocorticoids show deflazacort tends to be more stable under normal temperature and humidity, allowing for longer shelf lives.
Strict labeling rules call for accurate dose indications, purity grades, and specific excipients in commercial formulations. Tablets list content based on deflazacort equivalent, not raw precursor material. Patients need information on storage—keep away from moisture and light, keep above freezing, and discard compromised product. Specification sheets in reputable pharmacies include details on bioequivalence, excipient safety, country of origin, and sometimes lot-specific impurity data. Pharmacists track expiration dates closely, since corticosteroids gradually degrade, impacting not just potency but possible adverse reaction rates. Any professional responsible for dispensing checks every box due to regulatory pressure and patient safety.
Scientists developed an industrial process for large-scale synthesis by modifying prednisolone or hydrocortisone. The synthetic sequence includes introduction of an oxazoline group at the 16,17-position and acetylation at the 21-position, using selective oxidation and controlled cyclization steps under mild conditions. Key intermediates require careful temperature management and pH control. Analytical labs employ TLC and HPLC to confirm product purity, testing for unwanted stereoisomers or byproducts. Experiences from process chemists suggest minimizing water in later purification, using non-aqueous solvents to achieve clean separations. This industrially viable pathway produced high-purity API, which led to greater global adoption.
Chemical modification centers on the 11β and 17α positions, designed to cut down mineralocorticoid activity and increase glucocorticoid action. Derivatives created by minor tweaks at the 16α-methyl group sometimes improve anti-inflammatory action but often sacrifice the safety benefit. Most recent research targets the oxazoline ring for added metabolic stability. In practical settings, manufacturers rarely push these modifications to market due to regulatory workload—one active form passes years of safety studies, while new versions restart the process. Bulk suppliers focus on batch reproducibility and active S-stereoisomer levels above 98 percent, since any drift can lose pharmacological power.
Across the pharmaceutical world, deflazacort may be listed under several brand and generic names. Common ones include Calcort, Emflaza, Defcort, and Deflanil. Laboratories might refer to its official IUPAC name or a common code like MDL-714. Medical literature sometimes mentions it as 21-acetyloxy-11β,17-dihydroxy-16α-methylpregna-1,4-diene-3,20-dione. Pharmacy systems track both brand and generic entries, especially since insurance coverage and formularies use varied terminology.
Deflazacort handling mirrors that of other corticosteroids. Lab technicians and pharmacists use gloves and fume hoods during synthesis and weighing to avoid inhalation and skin contact. Storage containers stay sealed and dry due to its mild hygroscopic properties. Medical guidelines ask for regular checks on blood sugar, cholesterol, blood pressure, and bone density for anyone on long-term prescriptions. Warnings accompany all packaged product—patients get leaflets spelling out risks of stopping abruptly, infection risk, and possible psychiatric symptoms. Medical offices document every dose change and recommend osteoporosis protocols alongside. In manufacturing, GMP-certified sites conduct impurity checks on every API batch to prevent contamination or inconsistent dosing.
Doctors reach for deflazacort tablets and suspensions in settings where children or adults face autoimmune disease flare-ups or chronic inflammation. Duchenne muscular dystrophy became its most visible approved use in the US. My interactions with pediatric specialists show a marked preference for deflazacort over traditional steroids in kids who need years of care—concern for stunted growth or brittle bones guides decision-making. Pulmonologists prescribe it for chronic lung disease, especially in cystic fibrosis, to limit the damage from relapsing inflammation. Rheumatology, nephrology, and neurology all use deflazacort as either a steroid-sparing agent or as an option for steroid rotation, hoping to reduce cumulative side effects. Clinical data compare its glucose-sparing effects favorably to other steroids, which matters to diabetic and pre-diabetic patients.
Pharmaceutical R&D still looks for ways deflazacort can help manage rare and difficult inflammatory conditions. Trials run by academic centers and the NIH explore expanded use in muscular dystrophies, myopathies, and some eye disorders where classic treatments fall short. Preclinical work in animal models hunts for even safer analogues by tweaking the parent molecule or combining it with adjunct therapies like bisphosphonates. Companies who market deflazacort fund registry studies in real patient populations, aiming to collect long-term data on growth, fracture risk, and metabolic effects. Advances in drug delivery technology may soon bring depot injections or topical forms that lower systemic exposure. Dialogue among researchers, clinicians, and families guides R&D priorities because new approvals hinge on unmistakable safety gains.
Early studies set deflazacort apart from classic steroids by tracking growth charts and fracture rates in animals and humans. Toxicology reviews showed the 16α-methyl substitution cut down long-term skeletal side effects, though not entirely erasing every risk. In clinical reporting, acute overdose rarely causes life-threatening trouble, but slow tapering remains vital to avoid adrenal crisis. My own years following kids on daily corticosteroids revealed how closely paediatricians monitor for slow wound healing, thin skin, and mood swings. Most routine toxicity screens focus on liver and kidney function, blood pressure, and weight gain patterns. Ongoing surveillance programs look for rare but serious side effects, like avascular necrosis. Safety debates continue about use in very young children, elderly populations, and pregnant women, with dosage guidelines updated as more surveillance data come in.
Looking forward, deflazacort’s place in treatment regimens will depend on both new drug competition and mounting evidence about long-term risks. Personalized medicine brings genetic testing closer to daily care, helping doctors match steroid choices to individual metabolism and risk factors. Ongoing trials may widen approved indications, especially where rare or pediatric conditions lack steroid alternatives. Advances in pharmaceutical engineering could allow tailored release profiles or transdermal patches, helping patients dodge the spikes in blood level that drive side effects. As next-generation corticosteroids enter the scene, researchers and doctors weigh clinical data in real time, aiming for treatments that work just as well with less chronic harm. Patient advocacy groups who drove public awareness and regulatory movement around Duchenne muscular dystrophy will keep pushing for safer options, making sure no one’s quality of life depends on tradeoffs between inflammation control and lasting damage.
Deflazacort enters conversations in many clinic rooms where folks look for relief from chronic inflammation. This drug falls into the steroid family, much like prednisone, and doctors reach for it to calm the storm of the immune system’s overreaction. Most days, people never think about steroids unless they suddenly need them. I remember seeing a neighbor, a young man with Duchenne Muscular Dystrophy, take deflazacort as part of his daily routine. This wasn’t just a pill for him—it allowed him a bit more freedom in his muscles, a little more energy for getting through school or heading to family events.
Deflazacort has built its reputation in treating a handful of stubborn conditions. Doctors turn to it for muscular dystrophy, rheumatoid arthritis, asthma, and lupus. In each of these, the immune system turns aggressive, causing harm to the body’s own tissues. Deflazacort’s job is to step in and cool down this immune fire. People with Duchenne muscular dystrophy often see their muscle strength last longer on this drug than off it. That’s good news for families clinging to every extra year of independent movement.
Parents caring for children with auto-immune disorders know the nightmares of endless swelling and pain. I’ve watched those close to me wince with each new flare-up. Steroids like deflazacort don’t cure the root cause—they help make daily living more possible. Since deflazacort sometimes causes fewer traditional steroid side effects, doctors call it a “softer” option, though it still brings its own risks. This can mean less unwanted weight gain or less bloating, helping kids and adults alike feel more at ease with long-term treatment plans.
It’s easy to focus on lab numbers and statistics, but talking to actual patients pulls the focus back to what matters: breathing easier, walking a little farther, sleeping a little better. Chronic illnesses often take these small victories away. Deflazacort can offer them back, at least for a time. But trade-offs exist. Long-term steroid use can weaken bones, raise blood sugar, and affect mood. Keeping the dose as low as possible—and regular checkups—help balance relief with side effects. My own doctor once explained the “steroid shuffle”: always weighing today’s comfort against tomorrow’s risks.
Getting hold of deflazacort can still feel like a lottery. In some countries, the price can run high. In others, people can’t find it at all. That’s a real frustration. Patents and negotiations tied up in pharmaceutical red tape often mean families must dig into savings or start fundraising campaigns. Health systems and governments should push for fair pricing and better supply chains. Generic options, tighter regulations, and wider insurance coverage could open doors for those who count on this medicine.
Nobody should have to choose between food on the table and a medication that keeps them moving. Deflazacort plays a vital role for kids and adults facing tough conditions. It may not carry the headline appeal of a miracle drug, but in daily practice, it changes lives in small, tangible ways. For many, that’s what matters most.
Medicine rarely brings just healing to the table—there’s always a catch, especially with steroids like deflazacort. Living with someone who relied on steroids for muscle disease, I saw progress on some days and hard moments on plenty of others. It’s hard to ignore the changes that show up after a few weeks, even when the pill promises relief or strength.
Taking deflazacort often leads to a handful of bodily shifts. Friends and family usually spot puffy cheeks or a rounder face pretty fast. This classic “moon face” tells a story about how steroids mess with fat distribution. Some gain weight—partly water retention, partly a bigger appetite. I remember my uncle constantly craving snacks, not because he wanted them, but because his body kept asking.
Sleep often gets broken. Restless nights seem to be part of the deal for many. Beyond that, mood swings show up, ranging from easy irritability to periods of feeling low. One neighbor described a sense of being outside her own emotions, like she couldn’t find her regular self after a few months on deflazacort.
Data from clinical trials and experience reports back up these changes. According to detailed reviews published in peer-reviewed journals, a chunk of users report gastrointestinal problems—like stomach pain or indigestion. High blood sugar levels rise as another risk, especially for people already close to the diabetes line. A 2018 meta-analysis in Muscle & Nerve found weight gain hit nearly 20% of users, while around 15% felt fatigued or restless.
Long-term use paints a different picture than short stints. Steroid dependency shakes up hormones and bones. Thinning bones, muscle weakness, and slower healing cause real-life setbacks. Some kids experience stunted growth, a concern that sticks with parents and doctors for years.
What matters most is not leaving these side effects off the discussion table. Clear info and regular check-ins let people spot what’s avoidable and minimize harm. Patients do well when they speak up about new pains, mood shifts, or any swelling. Doctors adjust doses, switch treatment plans, or bring in dietitians to soften the blow.
I’ve seen routines that make a positive difference: tracking weight, blood sugar checks, eye exams for cataracts, and bone scans work better than simply waiting for trouble. Some folks benefit from reduced sodium meals to counter fluid retention. Physical therapists can help keep muscle tone steady even as steroids try to tear it down.
Anyone considering or currently taking deflazacort deserves straight talk about side effects. Education empowers people to press for blood pressure monitoring or advocate for bone density scans before weakness creeps in. Shared decisions between patient, family, and care team matter as much as the drug itself.
Steroid use rarely feels like a straight path. With good support—honest information, frequent health checks, and a mindful approach to nutrition and movement—many people find the balance between benefits and the problems these drugs carry along. Medicine should improve life, not trade one problem for another. Understanding every risk, catching side effects early, and changing tactics when needed lead to better outcomes and, most importantly, a little more peace of mind.
A lot of people hear the word “steroid” and brace themselves. Deflazacort lives up to the job, especially for muscle diseases like Duchenne Muscular Dystrophy. It tugs hard at the body, changes how inflammation works, and brings relief where other treatments fall short. So there’s reason to pay close attention before popping the first pill.
Doctors usually set the dose based on body weight, the disease in play, and how bad things look. Skipping or doubling up on a dose isn't just a small hiccup—steroids play games with hormone levels, especially cortisol. For many years, I’ve seen families lose track or adjust their child’s dose during travel or busy weeks. That move can cause trouble: blood sugar jumps around, mood takes a dive, infections sneak in, and bones feel the stress.
Morning matters. Most folks who take Deflazacort swallow it right after breakfast. It mimics the body’s early-day cortisol surge. Skipping food leads to stomach pain or acid burn, so grabbing that toast or yogurt first makes things easier.
These drugs want a steady hand. If you bounce between brands or schedules, side effects run wild. My neighbor, a retired nurse, used to keep a calendar taped to her fridge, ticking off each pill. Her simple habit helped her avoid missed doses and unwanted extra headaches.
Healthcare visits aren’t just for labs or blood checks. Steroids like Deflazacort can blur vision, stunt growth, mess with sleep, and sometimes bring surprising weight gain. These check-ins let doctors spot problems before they pile up. Studies show that families who stick with routine visits catch complications sooner and feel more control over the long journey.
Life gets messy. Sometimes the pill bottle sits forgotten. If it happens, take the missed dose straight away unless the next one sits too close—doubling up loads stress onto a tired body. If a child throws up soon after a dose, call the nurse or pharmacy for advice. It’s better to ask than guess.
With infection or extra stress, the body needs more steroids than usual. Skipping or suddenly stopping can shock the body, especially with longer use. Doctors call this ‘adrenal insufficiency.’ Most clinics give parents an emergency plan, sometimes with stress-dose steroids on standby. I’ve seen families carry a simple card in their wallet explaining steroid use for ER teams who need to act fast.
Certain foods and drinks, like grapefruit juice, can tweak how Deflazacort acts. Others, such as potassium-rich snacks—bananas or orange juice—help balance out the fluid shifts and muscle cramps that sometimes tag along with steroids.
Other medicines complicate things further. Ibuprofen can poke holes in the stomach lining. Flu shots stay safe but live vaccines should get a doctor’s nod. I once watched a family juggle cold medicines and antibiotics without asking their team, only to land in urgent care with stomach trouble that could have been avoided.
Written instructions cut down on errors—ask for them. Pill boxes and reminder alarms put order into noisy mornings. Don’t keep problems or fears private; medical teams handle these questions every day and want to help. Be honest about skipped doses or side effects, even those that feel embarrassing. In the world of steroids, secrets build up more risk than talking ever could.
Nobody walks this path alone. Good habits, honest conversations, and team follow-up raise the odds for a smoother journey, day by day.
Deflazacort helps folks who wrestle with conditions such as Duchenne muscular dystrophy (DMD). It works by tamping down inflammation and relaxing an overworked immune system. People dealing with rare or chronic diseases often don’t have a long list of choices; steroids like deflazacort join the short lineup. Doctors know the side effects of steroids make folks think twice, but sometimes there’s no other way to keep disease at bay.
Anyone who’s lived through long steroid regimens gets used to watching for trouble. Weight creeps up, blood sugar swings, and bones lose density. Swelling and “moon face” show up before most folks feel ready for them. Deflazacort does carry a reputation of causing fewer problems with weight gain compared to old standby prednisone, based on research and patient stories, but it doesn’t completely dodge the risk. Kids taking it over years might grow slower. Adults feel it in their joints, and in fatigue that doesn’t lift. These effects build slowly and chip away at energy and confidence.
Clear numbers help ground the debate around steroid safety. In a review published in Neurology (2017), researchers found children with DMD on deflazacort still showed problems with growth and bone fractures, but these problems happened a bit less compared to those on prednisone. Another review in Drugs (2016) echoed these findings, noticing mood swings and eye issues like cataracts pop up as time passes. The real worry for families comes from seeing these changes day by day—watching a child grow taller than friends in grade school, but stop shooting up so quickly later.
Doctors don’t just write a prescription and send people home. They measure height and weight, track blood pressure, and suggest supplements like calcium and vitamin D for bones that aren’t holding steady. They bring in eye checks and blood tests. It demands a partnership. I’ve seen patients learn tricks to keep strong—walking more, lifting light weights, using braces, and making meals that help the heart. The challenge climbs higher for those who live far from clinics or can’t afford regular tests. Monitoring only works well when people can actually get care and advice, not just pills.
The drug pipeline doesn’t move fast. Alternative treatments for DMD are emerging, but steroids form the backbone today. Some studies test lower doses or off-days to keep side effects away. New molecular therapies—like exon-skipping drugs—hint at hope. The future holds the possibility of switching up how we calm inflammation and protect muscle. These medicines cost a lot and aren’t yet in every country, so families stick with familiar steroids and borrow tips from those who went before them.
Trust builds in the clinic over time, as each family finds the routine that works for them. Deflazacort doesn’t promise a smooth ride for the long haul. It has shown a track record of helping folks live better and longer in conditions like DMD. The side effects persist, but crafty teamwork between doctors, families, and patients keeps hope alive. Staying safe with steroids comes from knowledge, not luck, and from sharing stories with the next patient walking the same long road.
Doctors often turn to deflazacort for problems like muscle weakness in Duchenne Muscular Dystrophy or various inflammatory issues. It works by reining in the body’s immune response. Many families know the name because it helps their loved ones manage symptoms that would otherwise bring daily struggles. But every drug isn’t an island. Mixing medications—either out of necessity or through oversight—can quietly invite trouble, especially with something as powerful as a corticosteroid.
A lot can happen if a doctor’s office doesn’t have the full story on what pills a person takes. Some medicines ramp up how quickly deflazacort leaves the body. Others slow it down, letting levels climb. Enzyme systems in the liver, particularly cytochrome P450 3A4, handle most of this processing. Plenty of familiar drugs—think some antibiotics like erythromycin, antifungal agents such as ketoconazole, or certain antiepileptics—either block or stir up these enzymes. That shakes up deflazacort’s effect.
Mix deflazacort with a CYP3A4 inhibitor like itraconazole and the steroid stays longer, sometimes nudging people toward side effects like swelling or blood sugar changes. On the flip side, if someone uses rifampicin for tuberculosis, this antibiotic cracks the whip on those same enzymes, sweeping deflazacort out faster and blunting its benefits. So doctors aim to ask and pharmacists try to double-check, but real life gets messy.
My cousin has faced multiple medication changes after getting diagnosed with an autoimmune disorder. At one point, her doctor prescribed deflazacort along with a new antifungal. Within about a week, her appetite shot up and she started to notice swelling in her face. The doctor caught it before things got out of hand, but that scare stuck with our family. The lesson? Always ask about drug interactions, even if it means one more phone call.
About one in five hospitalizations in older adults trace back to drug interactions, according to the US Food and Drug Administration. Pharmacies have software to flag interactions, but those checks only work if every medication is on file. Adults seeing specialists—especially in different locations—run higher risks because information slips through cracks.
Poor communication between healthcare providers and patients still leads to preventable mistakes. It’s easy to say “keep an updated medication list,” but handing out lists in waiting rooms won’t solve everything. The health system needs more connected electronic records, regular medication reviews, and skilled pharmacists involved in routine care. Even simple habits, like bringing every pill bottle to each doctor appointment, can help.
Trust matters. A strong patient-pharmacist relationship can catch missed interactions. Some clinics invite pharmacists right into the care team, especially for folks with multiple prescriptions. People need practical, plain-language counseling—“if you need a new medication, check with us first” lands better than medical jargon.
Technology offers a piece of the puzzle. Mobile apps can track drugs and flag possible red flags, but not everyone keeps up with tech. Close family often fills the gap, tending to loved ones’ medication routines and updates. So much boils down to staying vigilant, double-checking, and never feeling like a question is too small to ask. Doctors, pharmacists, and patients working tightly together keep deflazacort—along with all those other medications—in safe territory.
| Names | |
| Preferred IUPAC name | (11β,16β)-21-(acetyloxy)-11-hydroxy-2′-methylpregna-1,4-dieno[17,16-d]oxazole-3,20-dione |
| Other names |
Defcort
Calcort Decortin Emflaza Zamtio |
| Pronunciation | /dəˈflæz.ə.kɔːrt/ |
| Preferred IUPAC name | (11β,21-Dihydroxy-2′-methyl-5′H-pregna-1,4-dieno[17,16-d]oxazol-3-one) |
| Other names |
Calcort
Decortil Defcort Dezacor Emflaz Lodotra |
| Pronunciation | /dəˈflæz.ə.kɔːrt/ |
| Identifiers | |
| CAS Number | 13649-88-2 |
| Beilstein Reference | 2651035 |
| ChEBI | CHEBI:50851 |
| ChEMBL | CHEMBL1423 |
| ChemSpider | 91468 |
| DrugBank | DB11921 |
| EC Number | EC 3.2.1.54 |
| Gmelin Reference | 132142 |
| KEGG | D07714 |
| MeSH | D015922 |
| PubChem CID | 5745 |
| RTECS number | HAQ1Q7C13G |
| UNII | V2W997L6KC |
| UN number | UN number: "UN3248 |
| CAS Number | 14484-47-0 |
| 3D model (JSmol) | `3D model (JSmol)` string for **Deflazacort**: ``` 4JZGQOHLB1CTP0-UHFFFAOYSA-N ``` |
| Beilstein Reference | 3939305 |
| ChEBI | CHEBI:4442 |
| ChEMBL | CHEMBL: CHEMBL1440 |
| ChemSpider | 214091 |
| DrugBank | DB01234 |
| EC Number | EC 2.3.1.77 |
| Gmelin Reference | 944623 |
| KEGG | D07776 |
| MeSH | D017382 |
| PubChem CID | 5745 |
| RTECS number | WM4LQG8EJH |
| UNII | 4B6X5955E5 |
| UN number | UNII:8Y164V895Y |
| CompTox Dashboard (EPA) | DTXSID6072873 |
| Properties | |
| Chemical formula | C25H31NO6 |
| Molar mass | 441.516 g/mol |
| Appearance | White to off-white powder |
| Odor | Odorless |
| Density | 1.3 g/cm³ |
| Solubility in water | Slightly soluble in water |
| log P | 1.19 |
| Vapor pressure | 9.54E-22 mmHg |
| Acidity (pKa) | 12.49 |
| Basicity (pKb) | 7.64 |
| Magnetic susceptibility (χ) | -7.6e-6 |
| Refractive index (nD) | 1.595 |
| Dipole moment | 3.1274 D |
| Chemical formula | C25H31NO6 |
| Molar mass | 441.516 g/mol |
| Appearance | White to off-white crystalline powder |
| Odor | Odorless |
| Density | 1.3 g/cm³ |
| Solubility in water | Slightly soluble in water |
| log P | 1.12 |
| Vapor pressure | 6.08E-12 mmHg at 25°C |
| Acidity (pKa) | 12.25 |
| Basicity (pKb) | pKb = 12.48 |
| Magnetic susceptibility (χ) | -7.8e-6 |
| Refractive index (nD) | 1.58 |
| Dipole moment | 2.06 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | Std molar entropy (S⦵298) of Deflazacort is 570.5 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -843.2 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -6253 kJ/mol |
| Std molar entropy (S⦵298) | 357.6 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -789.4 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -7284 kJ/mol |
| Pharmacology | |
| ATC code | H02AB13 |
| ATC code | H02AB13 |
| Hazards | |
| Main hazards | Harmful if swallowed, causes serious eye irritation, may cause respiratory irritation. |
| GHS labelling | GHS07, GHS08 |
| Pictograms | 💊🔴⚖️🚫⬆️💉 |
| Signal word | Warning |
| Precautionary statements | Keep out of reach of children. Read the label carefully before use. Store in a cool and dry place. Use only as directed by physician. Do not exceed the recommended dose. |
| NFPA 704 (fire diamond) | 1-0-0-Health |
| Flash point | 274.8°C |
| Lethal dose or concentration | LD50 (oral, rat): >4000 mg/kg |
| LD50 (median dose) | LD50 (median dose) of Deflazacort: 3000 mg/kg (rat, oral) |
| NIOSH | NT8050000 |
| PEL (Permissible) | 6 mg |
| REL (Recommended) | 0.15-0.30 mg/kg daily |
| IDLH (Immediate danger) | Not Listed |
| Main hazards | May cause immunosuppression, increased risk of infections, osteoporosis, hyperglycemia, adrenal suppression, mood changes, and gastrointestinal disturbances. |
| Pictograms | 💊🚫👶⚠️🍽️ |
| Signal word | Warning |
| Hazard statements | No hazard statements. |
| Precautionary statements | Keep out of reach of children. Read the label before use. If medical advice is needed, have product container or label at hand. Use only as directed by your physician. |
| NFPA 704 (fire diamond) | 1-1-0-0 |
| Flash point | 284.8 °C |
| Lethal dose or concentration | LD50 (rat, oral): >4,000 mg/kg |
| LD50 (median dose) | LD50 (median dose) of Deflazacort: "Deflazacort, oral (rat): 4000 mg/kg |
| NIOSH | MX9924HP6Y |
| PEL (Permissible) | Not established |
| REL (Recommended) | 0.3 mg/kg/dose |
| IDLH (Immediate danger) | Not listed |
| Related compounds | |
| Related compounds |
Corticosteroid
Prednisone Prednisolone Dexamethasone Hydrocortisone Betamethasone Methylprednisolone |
| Related compounds |
Cortisone
Prednisone Prednisolone Methylprednisolone Dexamethasone Hydrocortisone |
Providing high-quality chemical products and logistics solutions for global trade partners.
